MediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• MediWound Ltd. (NASDAQ:MDWD) has received a consensus rating of "Moderate Buy" from analysts, with one hold rating and four buy recommendations.
• The average twelve-month price target for MediWound shares is $32.25, with recent prices ranging from $14.14 to $22.50.
• In its latest quarterly earnings report, MediWound reported an EPS of (\$1.23), missing the estimated consensus of (\$0.55), though revenue slightly exceeded expectations at $5.71 million.

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $32.25.

Several equities research analysts have recently issued reports on MDWD shares. Wall Street Zen lowered shares of MediWound from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Zacks Research downgraded shares of MediWound from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Oppenheimer started coverage on shares of MediWound in a research note on Monday, June 2nd. They issued an "outperform" rating and a $34.00 price objective for the company. Finally, HC Wainwright set a $31.00 price target on shares of MediWound and gave the stock a "buy" rating in a research note on Thursday, May 22nd.

MediWound Stock Up 0.3%

MediWound stock traded up $0.06 during mid-day trading on Monday, reaching $17.31. 19,323 shares of the company's stock traded hands, compared to its average volume of 81,082. The company has a market cap of $187.07 million, a price-to-earnings ratio of -6.55 and a beta of 0.25. The stock has a 50 day moving average of $18.33 and a two-hundred day moving average of $18.44. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.68). The business had revenue of $5.71 million for the quarter, compared to analysts' expectations of $5.68 million. MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. As a group, sell-side analysts forecast that MediWound will post -2.66 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp increased its stake in MediWound by 94.6% in the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock worth $2,577,000 after buying an additional 70,367 shares during the period. Bank of America Corp DE increased its stake in MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock worth $141,000 after buying an additional 2,178 shares during the period. Charles Schwab Investment Management Inc. increased its stake in MediWound by 17.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 22,468 shares of the biopharmaceutical company's stock worth $349,000 after buying an additional 3,343 shares during the period. Silverberg Bernstein Capital Management LLC increased its stake in MediWound by 13.1% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company's stock worth $1,613,000 after buying an additional 12,060 shares during the period. Finally, GAMMA Investing LLC increased its stake in MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares during the period. Hedge funds and other institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.